STI571: A paradigm of new agents for cancer therapeutics

Michael J. Mauro, Michael O'Dwyer, Michael C. Heinrich, Brian J. Druker

Research output: Contribution to journalArticlepeer-review

200 Scopus citations


STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.

Original languageEnglish (US)
Pages (from-to)325-334
Number of pages10
JournalJournal of Clinical Oncology
Issue number1
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'STI571: A paradigm of new agents for cancer therapeutics'. Together they form a unique fingerprint.

Cite this